Datapoint: J&J Scores Label Expansion for Stelara

The FDA this week expanded Johnson and Johnson’s Stelara’s psoriatic arthritis label, expanding its use to pediatric patients aged six and older. Stelara first launched in 2009 as a therapy for moderate to severe plaque psoriasis, and has since expanded across the immunology space. For the treatment of psoriatic arthritis, virtually all insured lives (99%) have covered or better access to Stelara under the pharmacy benefit. About 40% of those lives have preferred access to Stelara, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 8/3/22

0

0

0 Comments

0

0

• Datapoint